Printer Friendly

CURTAIN OPENS ON SOMANETICS' WINDOW TO THE BRAIN WITH THE START OF INVOS 3100 CEREBRAL OXIMETER COMMERCIAL SHIPMENTS

 TROY, Mich., May 17 /PRNewswire/ -- Somanetics Corporation (NASDAQ-NMS: SMTS) has commenced commercial shipments of its INVOS(R) 3100 Cerebral Oximeter, announced Gary D. Lewis, chairman, president and chief executive officer. Often referred to as the "window to the brain,"(TM) the Cerebral Oximeter and disposable SomaSensor(R) offer medical professionals the ability to look beyond a patient's scalp and skull to gather information about the brain using low-intensity, visible and near infrared light. The Cerebral Oximeter is the first commercial product of its kind to safely measure oxygen saturation of the blood in portions of an adult's brain, noninvasively, directly and continuously.
 "The Cerebral Oximeter is a simple idea, long overdue," said Professor Charles McCollum, M.D., Professor of Surgery at the University of South Manchester in the United Kingdom. "The Cerebral Oximeter has immense potential for making the surgery I perform as well as many other types of surgical situations much safer."
 The new technology of the INVOS 3100 Cerebral Oximeter and SomaSensor provides immediate, sensitive information about the patient. The brain is the human organ least tolerant of oxygen deprivation. Without sufficient oxygen, brain cells die within minutes, possibly resulting in paralysis, severe and complex disabilities, irreversible brain damage or death. The Cerebral Oximeter is expected to help surgeons, anesthesiologists and other medical personnel take early corrective action when needed. In addition, the prevention of certain types of brain injuries can result in shorter patient hospital stays and decreased costs related to patient care after surgery.
 "The Cerebral Oximeter makes our lives easier. Operations that used to be tense have become more relaxed, because we now know what's going on in the brain," said Professor McCollum, a physician who has conducted research with the Cerebral Oximeter.
 Somanetics' method of measuring oxygen saturation with the disposable SomaSensor is noninvasive and avoids the potential for associated infection and protects medical personnel from further exposure to blood contamination or communicable diseases, particularly AIDS.
 The Cerebral Oximeter and related SomaSensor deliveries are being made to the company's global network of specialty dealers of anesthesiology, cardiovascular and neurosurgical products. Distributors currently cover the entire United States and 30 international markets.
 According to Lewis, the company's initial U.S. target market is approximately 26,000 critical care sites in operating rooms, intensive care units and post-anesthesia care units. Additionally, the company expects its exports, to Europe, Asia, the Americas and Australia/ New Zealand, to comprise an increasing portion of its sales, initially approximately 50 percent.
 Somanetics Corporation is headquartered in Troy and currently has 46 employees. The company's common shares and Class B Warrants are traded publicly on the NASDAQ National Market System under the symbol SMTS and SMTSZ, respectively.
 -0- 5/17/93
 /CONTACT: Mary Ann Robb, director of Corporate Communications, Somanetics Corporation, 313-689-3050/
 (SMTS)


CO; Somanetics Corporation ST: Michigan IN: MTC SU: PDT

DH -- DE003 -- 8979 05/17/93 08:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 17, 1993
Words:480
Previous Article:NEW VIDEO EXPLORES INTIMATE DETAILS OF ADOPTION THROUGH ACTUAL FOOTAGE
Next Article:MAGNETS AN ATTRACTIVE WEAPON IN THE WAR ON CROOKED TEETH
Topics:


Related Articles
SOMANETICS ANNOUNCES CLEARANCE TO MARKET INVOS 3100 CEREBRAL OXIMETER
'OUTSIDE LOOKING IN' -- A WINDOW TO THE BRAIN
SOMANETICS CORPORATION SECURITIES WILL TRADE IN NASDAQ NATIONAL MARKET
SOMANETICS ANNOUNCES PATENT AWARD
SOMANETICS ANNOUNCES EXTENDED REDEMPTION PERIOD FOR CLASS B WARRANTS AND REVISED SHIPPING SCHEDULE
SOMANETICS CORPORATION ANNOUNCES YEAR-END RESULTS
SOMANETICS INTERRUPTS SHIPMENTS OF CEREBRAL OXIMETER
SOMANETICS TO FILE NEW 510(k), EXTENDS REDEMPTION DATE OF CLASS B WARRANTS AND EXPECTS TO RESUME INTERNATIONAL SALES
SOMANETICS ANNOUNCES FIRST COMMERCIAL EVALUATION IN THE U.S. OF THE INVOS(R) 3100A CEREBRAL OXIMETER
Somanetics Announces International Introduction of the Next Generation Cerebral Oximeter Patient Monitoring System

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters